Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday

Benzinga · 09/26 14:23
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday.
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA approved PALSONIFY.
Also, Baird and JMP Securities raised their respective price targets on the stock.
Crinetics Pharmaceuticals shares jumped 23.7% to $44.41 on Friday.
Here are some other big stocks recording gains in today’s session.
- Aquestive Therapeutics, Inc. (NASDAQ: AQST) gained 21.2% to $6.38.
- Perpetua Resources Corp. (NASDAQ: PPTA) rose 18% to $22.43 after the company issued an update today on its ongoing efforts to help secure the American antimony supply chain.
- Robo.ai Inc. (NASDAQ: AIIO) gained 14% to $2.77.
- Quantum Computing Inc. (NASDAQ: QUBT) rose 13% to $23.15.
- SkyWater Technology, Inc. (NASDAQ: SKYT) shares jumped 12% to $17.23.
- Scholar Rock Holding Corporation (NASDAQ: SRRK) surged 10.8% to $38.23. Scholar Rock Holding recently announced that the FDA issued a Complete Response Letter for the apitegromab Biologics License Application for the treatment of patients with spinal muscular atrophy.
- Avino Silver & Gold Mines Ltd. (NYSE: ASM) gained 9.2% to $5.24.
- New Found Gold Corp. (NYSE: NFGC) shares rose 9.1% to $2.3347. New Found Gold confirmed at-surface high-grade core in Iceberg Excavation Channel Sampling Program.
- Gorilla Technology Group Inc. (NASDAQ: GRRR) gained 7% to $20.10. Gorilla Technology recently signed a three-year $1.4 billion deal to build AI data centers in Southeast Asia.
- BlackBerry Limited (NYSE: BB) rose 6.6% to $4.9596 after the company reported second-quarter EPS and sales above estimates and raised its FY2026 adjusted EPS guidance.
- Carpenter Technology Corporation (NYSE: CRS) rose 6.6% to $247.84.
Read This Next:
Photo via Shutterstock
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.